Unity Biotechnology (UBX) Price & Analysis

Compare

783 Followers

UBX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.10 - $3.10

Previous CloseN/A

Volume348.46K

Average Volume (3M)1.34M

Market Cap

$1.74M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Aug 12, 2025

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding17,212,172

10 Day Avg. Volume2,978,694

30 Day Avg. Volume1,344,646

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$1.50

Price Target Upside1263.64% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Patient OutcomesApproximately 40% of UBX1325 patients did not require supplemental anti-VEGF through week 36, supporting the novel retinal mechanism.

Vision ImprovementUBX1325 demonstrated vision gains comparable and statistically non-inferior to aflibercept at week 36 considering difficult to-treat DME patients with favorable safety and tolerability.

Bears Say

Data ImbalanceThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Study Endpoint MissThe Phase 2B ASPIRE study of intravitreal foselutoclax (UBX1325) in diabetic macular edema patients did not meet the non-inferiority analysis specifically at the average of weeks 20 and 24 for the primary analysis.

Unity Biotechnology News

Four new option listings and three option delistings on July 9th

New option listings for July 9th include DTCBD Stock (DTCBD), Everus Construction Group Inc (ECG), Emera Incorporated (EMA),...

22d ago

ECG

EMA

Unity Biotechnology Faces Nasdaq Delisting and Leadership Changes

An announcement from Unity Biotechnology ( ($UBX) ) is now available. On June 27, 2025, UNITY Biotechnology was...

1M ago

UBX

Unity Biotechnology Faces Nasdaq Delisting Notice

The latest announcement is out from Unity Biotechnology ( ($UBX) ). On June 18, 2025, Unity Biotechnology received...

1M ago

UBX

Leidos, SoundHound, CMC, Unity, Southwest: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($LDOS) ), ( ($SOUN) ), ( ($CMC) ), ( ($UBX)...

2M ago

CMC

LUV

Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results

Matthew Caufield, an analyst from H.C. Wainwright, maintained the Hold rating on Unity Biotechnology (UBX – Research Report)....

2M ago

UBX

Unity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Unity Biotechnology (UBX) to Neutral from Buy with a price target of $2, down from...

2M ago

UBX

Unity Biotechnology downgraded to Neutral from Outperform at Mizuho

Mizuho analyst Salim Syed downgraded Unity Biotechnology (UBX) to Neutral from Outperform with a price target of $1,...

3M ago

UBX

Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study

An announcement from Unity Biotechnology ( ($UBX) ) is now available. On May 2, 2025, UNITY Biotechnology’s Board...

3M ago

UBX

Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE

UNITY Biotechnology (UBX) announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in...

3M ago

UBX

Unity Biotechnology Reports Q1 2025 Financials and Study Updates

Unity Biotech ( ($UBX) ) has released its Q1 earnings. Here is a breakdown of the information Unity...

3M ago

UBX

Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study

UNITY Biotechnology (UBX) announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study...

3M ago

UBX

Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Unity Biotechnology (UBX – Research Report) today and...

3M ago

UBX

Unity Biotechnology reports Q1 EPS (43c), consensus (40c)

Cash, cash equivalents and marketable securities totaled $16.9M as of March 31 compared with $23.2M as of December...

3M ago

UBX

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $8...

4M ago

UBX

UBX FAQ

What was Unity Biotech’s price range in the past 12 months?

Unity Biotech lowest stock price was $0.10 and its highest was $3.10 in the past 12 months.

What is Unity Biotech’s market cap?

Unity Biotech’s market cap is $1.74M.

When is Unity Biotech’s upcoming earnings report date?

Unity Biotech’s upcoming earnings report date is Aug 12, 2025 which is in 12 days.

How were Unity Biotech’s earnings last quarter?

Unity Biotech released its earnings results on Apr 22, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.03.

Is Unity Biotech overvalued?

According to Wall Street analysts Unity Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unity Biotech pay dividends?

Unity Biotech does not currently pay dividends.

What is Unity Biotech’s EPS estimate?

Unity Biotech’s EPS estimate is -0.17.

How many shares outstanding does Unity Biotech have?

Unity Biotech has 17,212,172 shares outstanding.

What happened to Unity Biotech’s price movement after its last earnings report?

Unity Biotech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went up 1.02%.

Which hedge fund is a major shareholder of Unity Biotech?

Currently, no hedge funds are holding shares in UBX

Unity Biotechnology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-231.27%

Trailing 12-Months

Asset Growth

-48.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unity Biotech

Unity Biotechnology (UBX) is a biotechnology company focused on developing therapeutics to treat age-related diseases. The company's primary aim is to extend healthspan, the period during which individuals remain healthy and free from age-related ailments. Unity Biotechnology's core products target senescent cells, which are cells that have stopped dividing and can contribute to various age-related diseases. By focusing on senescence biology, Unity seeks to develop innovative treatments for conditions such as osteoarthritis and other chronic diseases associated with aging.

Unity Biotechnology (UBX) Earnings & Revenues

UBX Earnings Data >

UBX Stock 12 Month Forecast

Average Price Target

$1.50

▲(1263.64%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Aug<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.46769230769230774,0.5953846153846154,0.7230769230769232,0.8507692307692307,0.9784615384615385,1.1061538461538463,1.2338461538461538,1.3615384615384616,1.4892307692307694,1.616923076923077,1.7446153846153847,1.8723076923076925,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.42923076923076925,0.5184615384615385,0.6076923076923078,0.696923076923077,0.7861538461538462,0.8753846153846154,0.9646153846153847,1.0538461538461539,1.143076923076923,1.2323076923076923,1.3215384615384616,1.4107692307692308,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.39076923076923076,0.44153846153846155,0.49230769230769234,0.543076923076923,0.5938461538461539,0.6446153846153846,0.6953846153846153,0.7461538461538462,0.7969230769230768,0.8476923076923077,0.8984615384615384,0.9492307692307691,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.18,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >